How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD

  title={How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD},
  author={George Steiner},
  journal={Cardiovascular Drugs and Therapy},
  • G. Steiner
  • Published 16 September 2009
  • Medicine
  • Cardiovascular Drugs and Therapy
PurposeIntensive multifactorial risk factor intervention, targeting blood glucose, blood pressure and low-density lipoprotein cholesterol, is central to therapeutic management of type 2 diabetes. This strategy reduces, but does not eliminate the risk for cardiovascular complications, and microvascular complications such as diabetic retinopathy and nephropathy still continue to develop or progress. Fibrates have been shown to be effective in managing mixed dyslipidemia characterized by elevated… 

Cardiovascular disease in diabetes mellitus: risk factors and medical therapy.

Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease.

The circulating angiopoietic CPCs, EPCs, and matEPCs in T2DM patients with DR had a different regulations, with increasing relative differences occurring in proliferative DR, apparently depending on the macrovascular comorbidities.

Triglycerides and Amputation Risk in Patients With Diabetes

Hypertriglyceridemia is a significant risk factor for LEA in diabetic patients even after controlling for known socioeconomic, health behavioral, and clinical factors and this previously unrecognized clinical risk needs to be further investigated.

A Comprehensive Review on the Drug: Fenofibrate

The present review has discussed the historical development, pharmacology, analytical profile with its physicochemical properties and ongoing research scenario on this API.

Triglycerides and Amputation Risk in PatientsWith Diabetes Ten-year follow-up in the DISTANCE study

The relationship between triglycerides and time to incident nontraumatic LEA, defined by primary hospitalization discharge or procedures, was evaluated using Cox proportional hazards models.

Role of the Peroxisome Proliferator Activated Receptors in Hypertension

This review of nuclear receptors focuses on the PPAR (peroxisome proliferator-activated receptor) family of adopted orphan receptors paying special attention to PPARγ, the isoform with the most compelling evidence as an important regulator of arterial blood pressure.

Dexmedetomidine protects from post-myocardial ischaemia reperfusion lung damage in diabetic rats

It is confirmed that dexmedetomidine has protective effects against the lung damage resulting from ischaemia/reperfusion in diabetic rats.



Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.

Lipoprotein Management in Patients With Cardiometabolic Risk

It is unclear whether lipoprotein parameters other than LDL or non-HDL cholesterol provide clinically significant additional prognostic information regarding CVD risk, yield more information about the effectiveness of therapy, or indicate more appropriate treatment targets.

Effect of a multifactorial intervention on mortality in type 2 diabetes.

In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.

Effects of intensive glucose lowering in type 2 diabetes.

The use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events and identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present.